Search ARM

Inherited Blood Disorders & Regenerative Medicine

This report provides industry specific statistics compiled from gene therapy, gene editing, cell therapy, and other regenerative medicine companies active in developing therapies for inherited blood disorders and provides context for the potential of regenerative medicine to improve upon the current standard of care.

This report provides industry specific statistics compiled from gene therapy, gene editing, cell therapy, and other regenerative medicine companies active in developing therapies for inherited blood disorders and provides context for the potential of regenerative medicine to improve upon the current standard of care.

As of March 2019:

There are 31+ companies worldwide working on regenerative medicine therapies for inherited blood disorders, including 18 clinical-stage companies.

There are currently 50+ products in active development with 38 clinical trials ongoing, including five in Phase III.

There are more than 20 million patients living with inherited blood disorders worldwide.

Full Report Here

38+

Clinical trials underway
worldwide as of March 2019

PH. 1

7

PH. 1/2

24

PH. 2

2

PH. 3

5

Clinical Trials by Technology Type

AAV Vector Gene Therapies

Lentiviral Vector Gene Therapies

Gene Editing Technologies

Cell Therapy

Clinical Trials by Indication

Companies Active in Developing Regenerative Medicines for Inherited Blood Disorders

Financings

Global Financings for Regenerative Medicines for Inherited Blood Disorders

Total Global Financings

Inherited Blood Disorders

2018

$2.3 Billion

26%

Increase from 2017

Infographics

View Full Report ARM Members Active in Inherited Blood Disorders